Jiaoti Huang, M.D., Ph.D

Jiaoti Huang, M.D., Ph.D.

Professor of Pathology and Urology Director of Urologic Pathology Department of Pathology & Laboratory Medicine David Geffen School of Medicine at UCLA 10833 Le Conte Avenue, 13-229 CHS Los Angeles, CA 90095-1732 Phone: 310-267-2264 E-mail: [email protected]

Education: M.D. Anhui Medical University, Hefei, China, 09/78-08/83 M.S. Institute of Radiation Medicine, Beijing, China, 09/83-08/86 Ph.D. New York University School of Medicine, New York, NY, 09/87-08/91

Research Training: 1. Graduate Program, Institute of Radiation Medicine, Beijing, China, 09/83-08/86 2. Ph.D. Program, Molecular and Cellular Biology, New York University School of Medicine, New York, NY, 09/87-08/91 3. Leukemia Society of America Postdoctoral Fellow, Department of Pharmacology, New York University School of Medicine, New York, NY, 09/91-11/94 4. Leukemia Society of America Postdoctoral Fellow, Dept of Medicine, Yale University School of Medicine, New Haven, CT, 12/94-06/95

Clinical Training: Residency Anatomic and Clinical Pathology Residency Program, New York University Medical Center, New York, NY, 07/95-06/99 Chief Residency Department of Pathology, New York University Medical Center, New York, NY 07/98-06/99 Fellowship Oncologic Surgical Pathology Fellowship Program, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, 07/99-06/00

Academic Appointments: 1. Assistant Professor, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, July 2000-Sept 2005 2. Associate Professor, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, Oct 2005-2007 3. Associate Professor of Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, Oct 2006-2007 4. Associate Professor of Urology, Department of Urology, University of Rochester Medical Center, Rochester, NY, Oct 2006-2007 5. Professor of Pathology, Urology and Oncology, University of Rochester Medical Center, Rochester, NY, Feb 2008-Aug. 2008 6. Co-Director, Genitourinary Pathology Fellowship Program, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, July 2002-Aug. 2008 7. Adjunct Professor, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Sept. 2008-present 8. Professor and Director of Urologic Pathology, Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Sept. 2008-present 9. Professor of Urology, UCLA David Geffen School of Medicine, Sept. 2009-present 10. Co-Director, Pathway Pathology Laboratory, UCLA Institute of Molecular Medicine (IMED), June 2009-present 11. Member, Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, Oct 2009-present 12. Member, UCLA Jonsson Comprehensive Cancer Center, January 2010-present

Hospital Appointments: 1. Attending Pathologist, Strong Memorial Hospital, University of Rochester, July 2000-2008 2. Director, Clinical Immunohistochemistry Laboratory, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, July 2003-2008 3. Attending Pathologist, UCLA Ronald Reagan Medical Center, Sept. 2008-present 4. Director of Urologic Pathology, UCLA Ronald Reagan Medical Center, Sept. 2008-present

Other Appointments: 1. Staff Scientist, Institute of Radiation Medicine, Beijing, China, 09/86-08/87 2. Consultant Pathologist, ImPath, Inc., New York, NY, 07/99-06/00 3. Member, Scientific Advisory Board, Egenix, Inc., 10/02-present 4. Chair, Scientific advisory Board, Egenix, Inc., 06/04-06/08 5. Deputy Chair, Scientific advisory Board, Egenix, Inc., 06/08-present 6. Visiting Professor, Anhui Medical University, China, August 2009-present

Study Sections: 1. Study Section Member, Department of Defense Prostate Cancer Research Program, 2003. 2. Study Section Member, J&J Discovery Fund, University of Rochester, 2005, 2006 3. Scientific Reviewer, Roy J. Carver Charitable Trust, December 2006 4. Scientific Reviewer, Laboratory Support Center, Clinical and Translation Science Institute (CTSI), University of Rochester, 2007 5. Study Section Member, SPORE applications in Prostate, Breast and Skin cancers, National Cancer Institute, February 2007 6. Scientific Reviewer, Head and Neck SPORE supplement funds, National Cancer Institute, May 2007 7. Study Section Member, Department of Defense Prostate Cancer Research Program, 2007 8. Study Section Member, Department of Defense Breast Cancer Research Program, 2008 9. Study Section Member, SPORE in Prostate, Ovarian, Pancreatic and Gastrointestinal Cancers, National Cancer Institute, 2008 10. Scientific Reviewer, The Prostate Cancer Research Foundation, London, 2008 11. Study Section Member, SPORE in Skin and Prostate Cancers, National Cancer Institute, 2010 Services in Professional Organizations: 1. Committee Member for Stipend Award, International Society of Urologic Pathology, 2008- 2010 2. Cadre Leader for Genitourinary Pathology, CALGB (The Cancer and Leukemia Group B, a national clinical research group sponsored by the National Cancer Institute).

Areas of Clinical Expertise: 1. Genitourinary Pathology 2. General Surgical Pathology 3. Oncologic Surgical Pathology 4. Immunohistochemistry

Editorial Boards and Journal Reviewers: 1. Member, Overseas Editorial Board, Chinese Journal of Pathology, 07/02-present 2. Member, Overseas Editorial Board, Journal of Clinical and Experimental Pathology, 07/05- present 3. Editorial Board Member, Asian Journal of Andrology, 04/2007-present 4. Senior Editorial Board Member, American Journal of Translational Research, 2009-present 5. Senior Editorial Board Member, American Journal of Cancer Research, 2010-present 6. Executive Editorial Board Member, International Journal of Clinical and Experimental Pathology, 04/2007-present 7. Editorial Board Member, Analytic and Quantitative Cytology and Histology, 03/2007- present 8. Editorial Board Member, The Open Prostate Cancer Journal, 09/08-present 9. Editorial Board Member, Chinese Journal of Urology, 09/10-present 10. Journal reviewer for: Cancer Research, Clinical Cancer Research, Prostate, Applied Immunohistochemistry and Molecular Morphology, Asian Journal of Andrology, American Journal of Pathology, Archives of Pathology and Laboratory Medicine, Analytical and Quantitative Cytology and Histology, PloS Medicine, Human Pathology, International Journal of Clinical and Experimental Pathology, British Journal of Cancer, Endocrine- Related Cancer, Journal of Cellular and Molecular Medicine, Endocrinology, Journal of Anatomy, Oncogene, Genes and Cancer, Prostate Cancer and Prostatic Diseases, The Open Prostate Journal, BMC Urology, Journal of Thoracic Oncology, BMJ Case Reports, Cancer Biomarkers, Cell Cycle, Cancer, PNAS

Professional Memberships: 1. United States and Canadian Academy of Pathology 2. American Association for Cancer Research 3. International Society of Genitourinary Pathology (committee member for the stipend award) 4. The Chinese Biological Investigators Society (life-time member)

Licensure: Full unrestricted medical license in the States of New York (License #: 211805) and California (License #: 53385)

Board Certification: Diplomat of American Board of Pathology, Combined Anatomic and Clinical Pathology, 2000

Honors and Awards: 1992-1995 Leukemia Society of America Postdoctoral Fellowship ($75,000) 1993 Scientific Exchange Award, Leukemia Society of America ($5,000) 1994 China-US Biochemistry and Molecular Biology Examination Application (CUSBEA) 2006 Eric A. Schenk Award for Excellence in Pathology Education, University of Rochester Medical Center (Once a year, voted by pathology residents and fellows) 2009 Roberta Nieberg Faculty Teaching Award, UCLA Pathology and Laboratory Medicine (Once a year, voted by pathology residents and fellows) Grant Support Finished grants: 1. Epigen Inc., “Expression of HCA protein in prostate cancer”. Direct cost of $10,950 and 25% indirect cost (2002-2003) Role: Principal Investigator 2. Epigen Inc., “Expression of HCA protein in metastatic prostate cancer”. Direct cost of $20,000 and 25% indirect cost (2003-2005) Role: Principal Investigator 3. R21 DK063126 “Inducible Gene Expression in Mouse Urothelium” (PI: Jay E. Reeder) Agency: NIH Period: Aug-01-2003 - Jul-01-2005 Award total: $315,000 %Effort: 5% Role: co-Principal Investigator 4. Laboratory Support Fund “Targeting neuroendocrine cells of prostate cancer” University of Rochester Clinical and Translation Science Institute Role: PI Period: 2008 Award total: $32,000 5. “RAD001 inhibition of neuroendocrine differentiation in prostate cancer” Novatis Pharmaceuticals Role: PI Period: 2007-2008 Award total: $4,200 6. Translational Research Funds, UCLA Department of Pathology (PI: Clebanoff) Period: 01/01/10 – 05/31/10 Title: Gene Profiling Studies to Identify molecular changes in pre-malignant prostate tissue” Award Total: $8,000 Role: Faculty Sponsor 7. Department of Defense Prostate Cancer Research Program PC061456 (PI: Huang) Period: 1/1/2007 – 7/31/2010 Title: The Function of PTP1B in Neuroendocrine Differentiation of Prostate Cancer (PI: Huang) Award total: $351,000 Percent effort: 20% Role: Principal Investigator 8. American Cancer Society RSG-07-092-01-TBE (PI: Huang) Period: 1/1/2007 – 12/31/2010 Title: Neuroendocrine Differentiation and IL-8 Signaling in Prostate Cancer (PI: Huang) Overall goals of the project: To study whether neuroendocrine differentiation and IL-8 signaling contribute to the progression of prostate cancer to the androgen-independent state, using both cell culture models and human tissue. Role: Principal Investigator Direct cost: $200,000/yr Percent effort: 40% Role: Principal Investigator 9. Development Research Award from UCLA Prostate Cancer SPORE (PI: Huang) Period: 2/1/2009-1/31/2011 Title: Targeting Neuroendocrine Cells of Prostate Cancer Overall goals of the project: To study if the elimination of neuroendocrine cells in mouse prostate cancer models may delay the development and progression of prostate cancer Award total: $65,000 Role: Principal Investigator 10. UCLA Research Services Research Fund (PI: Huang) Period: 5/1/2010 – 12/31/2010 Title: Gene Profiling Studies to Identify Molecular Changes in Basal, Luminal and Stromal Cells of Pre-Cancerous Prostate Tissue Overall goals of the project: To identify molecular alterations that represent early or precancerous stage in luminal, basal and stromal cells of the prostate Award total: $20,000 Role: Principal Investigator Current grants: 1. UCLA SPORE in Prostate Cancer (5P50CA092131-08) (PI: Reiter) Period: 1/7/2001 – 6/30/2012 Direct cost: $2,300,000/yr Percentage effort: 10% Role: Co-Director, Tissue Core 2. Prostate Cancer Foundation Challenge Award (PI: Witte) Period: 6/1/2008-5/30/2011 Title: Defining Targets and Biomarkers in Prostate Cancer Stem Cells: New Therapeutic Opportunities Direct cost: $750,000/yr Role: Co-PI 3. Prostate Cancer Foundation Creativity Award (PI: Rettig) Period: 5/1/2010-4/30/2012 Title: A Nano-Structured Platform for Enhanced Detection of CTCs in Prostate Cancer Patients Overall goals of the project: To detect and characterize circulating tumor cells in prostate cancer patients for the purpose of prognosis and targeted therapy Direct cost: $150,000/yr Role: Co-PI 4. Department of Defense Prostate Cancer Research Program PC101008 (PI: Huang) Period: 4/1/2011 – 3/31/2014 Title: The Function of Neuroendocrine Cells in Prostate Cancer Direct cost: $150,000/yr Percent effort: 10% Role: Principal Investigator 5. Cal-Tech-UCLA Joint Center for Translational Medicine Program (PI Huang) Period: 6/1/2011 – 5/31/2012 Title: Biomarkers for prostate cancer Direct cost: $50,000 Role: Principal Investigator Publications: 1. Huang J. and Tang Z. Measurement of estrogen receptor in the nuclei of bone marrow cells of male mice after the administration of estrogen. Bulletin Acad Mil Med Sci 1988; 2:24-26 2. Dolph PJ, Huang J, Schneider RJ. Translation by the adenovirus tripartite leader: elements which determine independence from cap-binding protein complex. J Virol 1990; 64:2669- 77 3. Huang J, Schneider RJ. Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine. Proc Natl Acad Sci U S A 1990; 87:18 7115-9 4. Huang J, Schneider RJ. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. Cell 1991; 65:271-80 5. Levy JB, Canoll PD, Silvennoinen O, Barnea G, Morse B, Honegger AM, Huang J, Cannizzaro LA, Park SH, Druck T, Huebner K, Barnea G, Sap J, and Schlessinger J. The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J Biol Chem 1993; 268:10573-81 6. Vogel W, Lammers R, Huang J, Ullrich A Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science 1993; 259:1611-4 7. Sorokin A, Mohammadi M, Huang J, Schlessinger J. Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. J Biol Chem 1994; 269:17056-61 8. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994; 79:1015-24 9. Huang J, Mohammadi M, Rodrigues GA, Schlessinger J. Reduced activation of RAF-1 and MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis. J Biol Chem 1995; 270:5065-72 10.Trachman JD, Huang J and Reem GH. Activation of human thymocytes induces the phosphorylation of protein tyrosine phosphatase 1C. C. R. Acad Sci Paris de la vie/Life Sciences 1995;318:367-74 11.Saric M, Applebaum RM, Culliford AT, Huang J, Scholes JV, Kronzon I. Massive Atrial Septal Lipomatous Hypertrophy. Echocardiography 1999; 16: 833–834 12.Gu M, Shi W, Huang J, Barakat, RR, Thaler HT and Saigo PE. Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma. Cancer (Cancer Cytopathology) 2000;90:143-7 13.Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous and metachronous tumors of the lung: Impact on management and prognosis. Ann Diagn Pathol 2001;5:321-329 14.Huang J, Behrens C, Wistuba II, Gazdar AF, and Jagirdar, J. Clonality of combined tumors: A molecular genetic study. Arch Pathol Lab Med 2002; 126: 437–441 15.Huang J and di Sant’Agnese PA. Neuroendocrine Differentiation in Prostate Cancer: An Overview. in Advances in Oncology: The Expanding Role of Octreotide I. Page 243-262. Ed. SWJ Lamberts and L Dogliotti. BioScientifica Ltd, Bristol, UK 2002 16.Liu Z, Huang J, Yan, Z and Tan, J: Application of flow cytometry in the diagnosis and differential disgnosis of lymphoma and leukemia. Chinese J Path 2002; 31:352-353 17.Lee Y-F, Lin W-J, Huang J, Messing EM, Chan FL, Wilding G, and Chang C. Activation of Mitogen-activated Protein Kinase Pathway by the Antiandrogen Hydroxyflutamide in Androgen Receptor-negative Prostate Cancer Cells. Cancer Res 2002; 62:6039-6042 18.Ni J, Chen M, Zhang Y, Li R, Huang J and Yeh S. Vitamin E sccinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery Biochem Biophys Res Commun 2003; 300:357-63 19.Chen TS, McNully M, Hulbert W, di Sant’agnese and Huang J. Renal oncocytosis presenting in childhood. A Case Report Intl J Surg Pathol 2003; 11:325-329 20.Daiss J, Carney J, Cartun R, Codington J, Erdrich C, Hinchman C, Huang J, Mauck J. and Schnipelsky P. Human Carcinoma Antigen: A Marker Useful for Discriminating between Benign Prostatic Hyperplasia and Prostate Cancer. J. Clinical Ligand Assay 2003; 26: 177- 180. 21.Li R, Yao JL, Bourne PA, di Sant’agnese PA and Huang J. Frequent expression of human carcinoma-associated antigen (HCA), a mucin-type glycoprotein, by cells of prostatic carcinoma. Arch Path Lab Med. 2004; 128: 1412-1417 22.Patton KT, Tretiakova MS, Yao JL, Papavero V, Huo L, Adley BP, Wu G, Huang J, Pins MR, Teh BT and Yang XJ. Expression of RON proto-oncogene in renal oncocytoma and chromophobe renal cell carcinoma. Amer. J. Surg. Pathol. 2004; 28:1045-50 23.Yao JL, Bourne PA, Yang Q, di Sant’Agnese PA and Huang J. Overexpression of Human Carcinoma-Associated Antigen (HCA) in Urothelial Carcinoma of the Bladder. Arch Path Lab Med. 2004;128:785–787 24.Hu Y-C, Yeh S-Y, Yeh S-D, Sampson EK, Li P, Hsu C-L, Ting H-J, Lin H-K, Wang L, Kim Y, Huang J, and Chang C. Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer. J Biol Chem 2004; 279:33438-46 25.Liang S, Yao JL, Bourne PA, di Sant’Agnese PA, Huang J and Lei J. Over-Expression of Human Carcinoma-Associated Antigen in Esophageal Adenocarcinoma and its Precursor Lesions. Amer J Clin Pathol 2004;122:747-51 26.Li R, Ni J, Yeh S, Bourne PA, Yao J, di Sant’agnese PA and Huang J. Cell culture block array for immunocytochemical study of protein expression in cultured cells. Applied Immunohistochemistry and Molecular Morphology 2005; 13:85-90 27.Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant’Agnese PA and Reeder JE. Differential expression of Interleukin-8 and its receptors in the neuroendocrine and non- neuroendocrine compartments of prostate cancer. Am J Pathol 2005; 166:1807-1815 28.Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY. Overexpression of Decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Amer J Clin Pathol 2005; 124:282-7 29.Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene. 2006; 25:1042-52 30.Huang J, Wu C, Yao JL and di Sant’Agnese PA. Neuroendocrine differentiation in prostate cancer. Proceedings of the 4th Asian-Pacific International Academy of Pathology Congress. Page 57-61. Ed. Wu BQ. Medimond S.r.l.. Bologna, Italy 2005 31.Huang J, Yao JL and di Sant’Agnese PA. Neuroendocrine Differentiation in Prostate Cancer. In Prostate Cancer: Principles and Practice. Page 143-150. Ed Kirby R, Partin AW, Feneley M, Parsons JK. Martin Dunitz Ltd (Taylor & Francis Group), London, UK 2005 32.Lei J., Bourne PA, di Sant’Agnese PA and Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma versus cholangiocarcinoma and metastatic carcinoma of the liver. Amer J. Clin Pathol 2006;125:519-525. 33.Wu C, Zhang L, Bourne PA, Reeder JE, di Sant’Agnese PA, Yao JL, Na Y and Huang J. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer. Prostate 2006; 66:1125-1135 . 34.Yao JL, Madeb R, Bourne PA, Lei J, Yang X, Tickoo, S, Liu Z, Tan D, Cheng L, Hatem F, Huang J, and di Sant’Agnese PA. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006; 30:705-12. 35.Huang J, Yao JL, di Sant’Agnese PA, Yang Q, Bourne PA, and Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006; 66:1399-406. 36.Johnson A, Conover D, Huang J, Messing ME, Ning R, O'Connell M, Rossi M, Sun T, Wu X and Reeder JE. Early Detection and Measurement of Urothelial Tumors in Mice. Urology 2006; 67:1309-14 37.Zhang Z, Rosen DG, Yao JL, Huang J, Liu J. Expression of p14(ARF), p15(INK4b), p16(INK4a), and DCR2 increases during prostate cancer progression. Mod Pathol. 2006; 19:1339-43 38.Wu C, Yao JL, di Sant’Agnese PA, Na Y, and Huang J. Neuroendocrine differentiation in prostate cancer. Chinese J Pathol 2006; 35 (9): 565-567 39.Wagner DG, Joseph J, Huang J and Xu H. Malakoplakia of the prostate on needle core biopsy: A case report and review of the literature. Int. J. Surg. Pathol. 2006 15:86-9 40.Markhardt KB, Rubens DJ, Huang J and Dogra VS. Sonographic features of Biliary Hamartomas with histopathological correlation. Journal of Ultrasound in Medicine 2006; 25:1631-3 41.Huang J, Wu C, di Sant’Agnese PA, Yao JL, Cheng L and Na Y. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quanti Cytol Histol 2007; 29: 128-138 42.Wagner DG, Yao JL, di Sant’Agnese PA, Cheng L, Lopez-Beltran A, Montironi R and Huang J. Soft tissue tumors in the prostate. Anal Quanti Cytol Histol 2007;29:341–350 43.Bhatt S, Huang J and Dogra VS. Littoral cell angioma of spleen: Radiologic-pathologic correlation. Am J Roentgenology 2007;188(5):1365-6 44.Oh WK, Tay MH and Huang J. Is There A Role For Platinum Chemotherapy In The Treatment Of Patients With Hormone-Refractory Prostate Cancer? Cancer 2007; 109(3):477-86 45.Liang JJ, Wang Z, Chiriboga L, Greco MA, Shapiro E, Huang H, Yang XJ, Huang J, Peng Y, Melamed J, Garabedian M, Lee P. The expression and function of androgen receptor coactivator p44 and protein arginine methyltransfersase 5 (PRMT5) in the developing testis and testicular tumors. J. Urol. 2007; 177(5):1918-22 46.Wu C, and Huang J. PI3 kinase-AKT-mTOR pathway is involved in neuroendocrine differentiation of prostate cancer. J. Biol. Chem. 2007; 282(6):3571-83 47.Wu C, Chen G, Na Y, Xin D, Yao JL, di Sant’Agnese PA and Huang J. The function of Interleukin-8 in prostate cancer. In Progress in Chemokine Research. Eds Linkes WP. Nova Science Publishers, Inc. New York, 2007. pp149-156. 48.Yao JL, Huang J and di Sant’Agnese PA. Small Cell Carcinoma of the Prostate. Diagnostic Histopathology. 2008; 14/3: 117-121 49.Cheng L, Zhang S, Wang M, Davidson DD, Morton MJ, Huang J, Zheng S, Jones TD, Beck SD, Foster RS: Molecular Genetic Evidence Supporting the Neoplastic Nature of Stromal Cells in “Fibrosis” After Chemotherapy for Testicular Germ Cell Tumors. J Pathol 2007: 213: 65-71 50.Podder TK, Sherman J, Li L, Joseph J, Rubens DR, Messing EM, Huang J and Yu Y. Mechanical properties of human prostate tissue in the context of surgical needle insertion. Int. J. Computer Assisted Radiology and Surgery 2007; 2 (Suppl I):S106-S108 51.Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin M-E, Ryan C, Huang J and Oh WK for the Prostate Cancer Clinical Trials Consortium (PCCTC). A Phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112:521-6 52. Hui P, Wang HL, Chu P, Yang B, Huang J, Baergen RN, Sklar J, Yang XJ, Soslow RA. Absence of Y chromosome in human placental site trophoblastic tumor. Mod Pathol. 2007; 20:1055-60 53.Li L, Yao JL, di Sant’Agnese PA, Bourne PA, Picken MM, Young AN, Shen SS and Huang J. Expression of Claudin-7 in Benign Kidney and Kidney Tumors. Intl. J. Clin. Exp. Pathol. 2008; 1:57-64 54.Simon RA, di Sant’Agnese PA, Palapattu GS, Singer ea, Candelario gd, Huang J and Yao JL. Mucinous Tubular and Spindle Cell Carcinoma of the Kidney with Sarcomatoid Differentiation Intl. J. Clin. Exp. Pathol. 2008; 1:180-184 55.Johnson AM, O’Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urology 2008; 8:7 56.Cheng L, Zhang S, Huang J and Na Y. A critical evaluation of the current classification system for non-invasive papillary urothelial carcinoma. Chin. J. Urol. 2008; 29: 137-140 57.Li L, Xu H, Spalding BO, Cheng L, Simon R, Yao JL, di Sant’Agnese PA, Bourne PA and Huang J. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol 2008; 39:1205-11 58.Cai Y, Lee Y-F, Li G, Liu S, Bao B-Y, Huang J, Hsu CL and Chang C. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J. Can. 2008; 123:195-201 59.Gobbo S, Eble JN, Huang J, Grignon DJ, Wang M, Martignoni G, Brunelli M, Cheng L: Schwannoma of the kidney. Mod Pathol 2008; 21:779-83 60.Lei JL, Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2008; 2:151-159 61.Liu B, Yu H-M I, Huang J, Hsu w. Co-opted Jnk/Sapk signaling in Wnt/b-catenin-induced tumorigenesis. Neoplasia 2008; 10: 1004-1013 62.Deng X, Liu H, Huang J, Cheng L, Keller E, Parsons S and Hu C. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression. Cancer Research 2008;68:9663-70 63.Simon RA, di Sant'Agnese PA, Huang L-S, Xu H, Yao JL, Yang Q, Liang S, Liu, J, Lee R, Cheng L, Oh WK, Palapattu G, Wei J, and Huang J. CD44 Expression is a Feature of Prostatic Small Cell Carcinoma and Distinguishes it from its Mimickers. Hum Pathol 2009;40:252-8 64.Wagner DG and Huang J. Small Cell Carcinoma of the Prostate. eMedicine from WebMD. Updated April 20, 2009. Available at: http://emedicine.medscape.com/article/1611899- overview. 65.Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang L-S, Yang Q and Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009 15;69:787-98 66. Sun Y, Niu J and Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009: 1:148-162 67.Huang J, Lee P, Mikami Y, Melamed J. Dysplastic ("in-situ") Lesions in multifocal renal oncocytomas (oncocytosis). Int J Clin Exp Pathol. 2009;2:583-7. 68.Huang J and Witte ON. A Seminal Finding for Prostate Cancer? New Eng. J. Med. 2010; 362: 175-6 69.Yuan P, Kadara H, Behrens C, Tang XM, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD and Wistuba II. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS ONE. 2010; 5(2): e9112 70.Lawson DA, Zong Z, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010; 107: 2610-5 71.Shen P, Wei W, Yang X, Zeng H, Li X, Yang J, Wang J, Huang J. The influence of percutaneous nephrolithotomy on human systemic stress response, SIRS and renal function. Urol Res. 2010 Mar 4. [Epub ahead of print] 72.Marks LS and Huang J. Re: Copy number analysis indicates monoclonal origin of lethal metastatic Prostate cancer. Words of Wisdom article. Eur. J. Urol. 2010; 57: 727-8 73.Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, Palapattu GS A novel in vitro assay of human prostate cancer tumor initiation. Prostate 2010; 70:1379-87 74.Brick A, Niu J, Huang J and Oh WK. Possibility for Platinum Chemotherapy Treatment for HRPC Patients? In Drug Management of Prostate Cancer. Eds Figg WD, Chau CH, Small EJ. Chapter 14, pp 153-61. Humana Press, NJ, 2010 75.Ward SC, Huang J, Tickoo S, Thung SN, Ladanyi, M and Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Modern Pathol 2010 23:1180-90 76.Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell-of-origin for human prostate cancer. Science 2010;329:568-71. 77.Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis. Clin Cancer Res. 2010; 16: 3875-86 78.Fang F, Christian WV, Gorman SG, Cui M, Huang J, Tieu K, and Ballatori N. Neurosteroid

transport by the organic solute transporter OSTα-OSTβ. J Neurochemistry 2010;115:220-33 79.Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T, Schafenacker AM, Huang J, Witte ON. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci U S A. 2010; 107: 17298-303 80.Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Ladan F, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, invasion,

metastasis and castration resistance. Nat Med 2010; 16:1414-20 PMID: 21057494 81.Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin Expression in Prostate: A Novel Finding. Cancer Investigation. 2011; 29:62-67 82.Sun Y and Huang J. Novel genetic loci associated with prostate cancer in the Japanese population. (Research Highlight Article) Asian J. Androl. 2010; 13:120-1 83.Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J and Li L-C. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer

Res 2010; 70:10182-91. 84.Cai H, Babic I, Wei X, Huang J and Witte ON. Invasive prostate carcinoma driven by c-Src

and androgen receptor synergy. Cancer Research 2011;71:862-72. PMID: 21135112 85.Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang H, Reiter RE, Huang J, and Witte ON. Methods for the purification and direct transformation of epithelial progenitor cells from primary human prostate. Nature Protocol 2011 (in press) 86.Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, Osunkoya AO, MacLennan GT, Montironi R, and Cheng L. ERG-TMPRSS2 Rearrangement is Shared by Concurrent Prostatic Adenocarcinoma and Prostatic Small Cell Carcinoma and Absent in Small Cell Carcinoma of the Urinary Bladder: Further Evidence Supporting Monoclonal Origin. Mod Pathol, 2011 Apr 15. [Epub ahead of print] PMID: 21499238 87.Wang S, Liu K, Liu J, Yu Z T-F, Xu X, Zhao L, Lee T, Lee EK, Reiss J, Lee Y-K, Chung LWK, Huang J, Rettig M, Seligson D, Duraiswamy KN, Shen C K-F, Tseng H-R. Highly Efficient Capture of Circulating Tumor Cells Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers. Angew Chem Int Ed Engl. 50:2857 (PMID: 21381170) 88.Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, Magyar CE, Huang J, Chai TC, Qiu S, Qiu Y. Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor

Prognosis in Patients with Cystectomy. PLoS One. 2011;6:e17778. PMID: 21408190 89.Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M, Montironi R, Lopez-Beltran A: The landscape of EGFR pathways and personalized management of nonsmall cell lung cancer. Future Oncology 2011; 7: 519-41. PMID:

21463141 90.Tai S, Sun Y, Squires JM, Zhang H, Oh K, Liang C-Z and Huang J. PC3 is a Cell Line

Characteristic of Prostatic Small Cell Carcinoma. Prostate. 2011 Mar 22. doi:

10.1002/pros.21383. [Epub ahead of print] PMID: 21432867 91.Natarajan S, Marks LS, Margolis D, Huang J, Macairan ML, Lieu P and Fenster A. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011 (in press) 92.Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA and Xu H. High Grade Neuroendocrine Carcinomas of the Lung Highly Express EZH2 but Carcinoids Do Not. Hum Pathol 2010 Feb 1. [Epub ahead of print] 93.Y. Sun, J. Perera, B. Rubin, J. Huang. SYT-SSX1 (Synovial Sarcoma Translocated) regulates PIASy to cause overexpression of NCOA3. Journal of Biological Chemistry 2011 Mar 24. [Epub ahead of print] PMID: 21454665 94.Mulholland MJ, Tran LM Li Y, Cai H, Morim A, Wang W, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H. Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. Cancer Cell. 2011 (in press) 95.Sun Y and Huang J. Cell of Origin of Prostate Cancer. Am J Can Res 2011 (in press)

Invited Lectures and Presentations: Invited by Academic Institutions: 1. Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine. Honors Program, Postgraduate School of New York University School of Medicine, 1990 2. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. Sacklar Institute of Biomolecular Medicine Research Seminar, New York University School of Medicine, 1991 3. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. Special Seminar, Howard Hughes Medical Institute, University of California School of Medicine at San Francisco, 1992 4. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. Howard Hughes Medical Institute, University of Washington at Seattle, 1992 5. Molecular pathology of lung cancer: Impact on prognosis and management. Grand Rounds, Department of Pathology, New York University School of Medicine, May 1998 6. Molecular pathology of lung cancer: Impact on prognosis and management. Combined Grand Rounds, Departments of Pathology, Cornell University School of Medicine and Memorial Sloan-Kettering Cancer Center, November 4, 1999 7. Molecular pathology of lung cancer: Impact on prognosis and management. Department of Pathology, Temple University School of Medicine, December, 1999 8. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated tumors. Cancer Research Institute, Chinese Academy of Medicine, Beijing, China, November, 2001 9. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated tumors. Beijing University School of Medicine, Beijing, China, November, 2001 10. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated tumors. Shanxi University School of Medicine, Taiyuan, China, November, 2001 11. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated tumors. Dalian University School of Medicine, Dalian, China, November, 2001 12. Contemporary classification of renal tumors. Dalian University School of Medicine, Dalian, China, November, 2001 13. Molecular Pathology of Lung Cancer. Department of Pathology, University of Chicago, November, 2002 14. Pathology of prostate cancer. Chaoyang Hospital, Capitol Medical University, Beijing, September 2003 15. Pathology of prostate cancer. The General Hospital of the Army, Beijing, September 2003 16. Neuroendocrine differentiation of prostate cancer. Roswell Park Cancer Center, July, 2004 17. Neuroendocrine differentiation of prostate cancer. Department of Urology, University of Rochester Medical Center, July, 2005 18. Neuroendocrine differentiation of prostate cancer. Department of Pathology, University of Rochester Medical Center, April, 2006 19. Neuroendocrine differentiation of prostate cancer. Department of Pathology, Emory University School of Medicine, May, 2006 20. Grand Round Speaker, Department of Pathology, New York University School of Medicine, March, 2007 (Neuroendocrine differentiation of prostate cancer). 21. Neuroendocrine differentiation of prostate cancer. Department of Pathology, School of Medicine, University of California at Los Angeles, June 2007 22. Departmental Seminar Speaker, Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy, Purdue University, September 2007 (Neuroendocrine differentiation of prostate cancer). 23. Departmental Seminar Speaker, Department of Pharmacology & Experimental Therapeutics, University of Maryland School of Medicine, June 2008 (Neuroendocrine cells in prostate cancer). 24. Grand round speaker, Department of Pathology, University of Nebraska, Omaha, NE, May 2010 (Neuroendocrine cells in prostate cancer) 25. Grand round speaker, Brady Urology Institute, Johns Hopkins University Hospital, Baltimore, MD, Dec 2010 (Neuroendocrine Differentiation in Prostate Cancer). I nvited by Local, National and International Conferences 1. Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine. Cold Spring Harbor Meeting: Translational Control. 1989; Cold Spring Harbor, New York 2. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein. American Society of Virology Annual Meeting, 1991; Fort Collings, Colorado 3. Molecular analysis of synchronous and metachronous tumors of the lung: Impact on management and prognosis. XXI International Congress of the International Academy of Pathology and 13th World Congress of Academic and Environmental Pathology, 1998; Nice, France 4. Fibrolamellar carcinoma of the liver: Immunohistochemical study of 11 cases and comparison with conventional hepatocellular carcinoma . 89th Annual Meeting, United States and Canada Academy of Pathology, New Orleans, LA, 2000 5. Prognostic significance of neuroendocrine phenotype expression in human prostate carcinoma. International Symposium on Prostate Cancer: Novel Strategies for a New Disease. Turin, Italy, September, 2003 6. Neuroendocrine differentiation of prostate cancer. The 4th Asia-Pacific IAP Congress, August 23 – 26, 2005 Beijing, China 7. Plenary Speaker, 13th Annual Meeting of the Chinese Urological Society, Shenyang, China, October 2006 (Recent advances in the pathology of urological tumors). 8. Invited participant, 11th Prouts Neck Meeting on Prostate Cancer "Emerging Strategies in Prostate Cancer Therapy", Prouts Neck, Maine, Nov 2-5, 2006 9. Plenary Speaker, Annual Meeting of the Chinese Society of Pathology, Chengdu, China, April 2007 (Immunohistochemistry in the differential diagnosis of undifferentiated tumors) 10. Invited Speaker and Session Co-Chair, Nanjing International Symposium of New Frontiers in Cancer Research, Nanjing, China, November 2007 (Neuroendocrine differentiation of prostate cancer). 11. Plenary Speaker, 14th Annual Meeting of the Chinese Urological Society, Xiamen, China, November 2007 (Neuroendocrine differentiation of prostate cancer). 12. Plenary Speaker, 15th Annual Meeting of the Chinese Urological Association, Kunming, China, September 2008 (Neuroendocrine cells in prostate cancer). 13. Plenary Speaker, 11th Mid-east Association of the Urology of China, Huangshan, China, June 2009 14. Invited Speaker, 16th Annual Meeting of the Chinese Urological Association, Chengdu, China, September 2009 (Recent advances in prostate cancer research). 15. The Function of Neuroendocrine Cells in Prostate Cancer. Prostate Cancer Foundation Scientific Retreat. Reno, NV, Sept 2009 16. The Function of Neuroendocrine Cells in Prostate Cancer. NCI Translational Science Meeting, Tyson Corer, VA. Nov 2009 17. Plenary speaker, 2010 Annual Scientific Meeting, the Association of Chinese American Physicians, New York, NY, May 2010 18. Plenary Speaker, Anhui Province Pathologists Association Meeting, China, Oct 2010 (Pathologic Diagnosis of Bladder Cancer) 19. Plenary Speaker, Anhui Province Urologists Association Meeting, China, Oct 2010 (Recent progress in prostate cancer and new therapies) 20. NCI Special Conference: Androgen Receptor in Prostate Cancer: Translating Biology into Clinical Practice. Arlington, VA. December 6-7, 2010 (Models of Tumor Development (e.g. cancer stem cells)) 21. P53 Pathway is Involved in the Pathogenesis of Small Cell Carcinoma of the Prostate. The second Innovative Minds in Prostate Cancer Today (IMPaCT) conference. Department of Defense Prostate Cancer Research Program (PCRP). Orlando, FL, March 2011 22. Individualized treatment for cancer. Invited Speaker. Technical Symposium of 49th anniversary of the Chinese-American Engineers and Scientists Association of Southern California (CESASC). San Gabriel, CA, April 2011 23. Tissue recombination technology in the study of tumor initiation cells for prostate cancer. Invited Speaker. Steering Committee Meeting, Intestinal Stem Cell Consortium (ISCC). Stowers Institute, Kansas City, Missouri, May 2011

Presentations in conferences (platform and poster presentations) 1. Huang J, Wistuba I, Behrens C, Gazdar AF, Kornacki S and Jagirdar J. Utilization of microdissection, PCR and LOH assay in the study of combined and collision tumors. 86th Annual Meeting, United States and Canada Academy of Pathology, 1997; Orlando, Florida 2. Huang J, Melamed M. Dysplastic (“in-situ”) lesions in multifocal renal oncocytomas. 89th Annual Meeting, United States and Canada Academy of Pathology, 1999; San Francisco, California 3. Vargas R, Bourn P and Huang J. Immunostaining for Calponin can completement 34E12 in prostatic biopsy. 90th Annual Meeting, United States and Canada Academy of Pathology, 2001; Atlanta, Georgia 4. Li R, Ni J, Yeh S, di Sant’agnese and Huang J. Cell block array: Development of a novel technique for the study of cultured cells by immunohistochemistry. 92th Annual Meeting, United States and Canada Academy of Pathology, 2003; Washington, D.C. 5. Li R, di Sant’agnese and Huang J. Frequent expression of human carcinoma-associated antigen (HCA), a mucin-type glycoprotein, by cells of prostatic carcinoma 92th Annual Meeting, United States and Canada Academy of Pathology, 2003; Washington, D.C. 6. H Li, L Zhang, I Ding, J Huang, PA diSant Agnese, H Lou, JY Lei. Over-Expression of Decoy Receptor 3 in Precancerous Lesions and Adenocarcinoma of the Esophagus. Mod Path. 2003. 17: S1; 121A. Presented at 94th Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC, March 2004. 7. S Liang, J Huang, PA Bourne, PA diSant Agnese, J Yao, JY Lei. Over-Expression of Human Carcinoma-Associated Antigen in Precancerous Lesions and Adenocarcinoma of the Esophagus. Mod Path. 2003. 17: S1; 121A-122A. Presented at 94th Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC, March 2004. 8. Yao JL, Alvarez VA, Bourne PA, Lei JY, di Sant’Agnese PA, and Huang J. Neuroendocrine Cells Correlate with Proliferation Centers in Benign Nodular Prostatic Hyperplasia. Mod Path. 2003. 17: S1; 185A. Presented at 94th Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC, and March 2004. 9. Yao JL, Li R, Bourne PA, Lei JY, di Sant’Agnese PA, and Huang J. Overexpression of Human Carcinoma-Associated Antigen (HCA) in Urothelial Carcinoma of the Bladder. Mod Path. 2003. 17: S1; 185A. Presented at 94th Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC, March 2004. 10. Yao JL, McClaskey JH, Quinn A, Bourne PA, Lei JY, di Sant Agnese PA and Huang J. Mucin Expression in Benign and Neoplastic Prostate Using Tissue Microarrays. Mod Path. 2003. 17: S1; 185A-186-A. Presented at 94th Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC, March 2004. 11. JY Lei, PA Bourne, J Huang, PA diSant Agnese.Thyroid Transcription Factor-1 as a Useful Marker in the Differential Diagnosis of Hepatocellular Carcinoma from Cholangiocarcinoma and Metastatic Carcinoma in the Liver. Mod Path. 2003. 17: S1; 306A. Presented at 94th Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC, March 2004. 12. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant’Agnese PA and Reeder JE. Differential expression of Interleukin-8 and its receptors in the neuroendocrine and non- neuroendocrine compartments of prostate cancer. 2005 AACR Annual Meeting, Anaheim, California, April 2004 13. Yao JL, Bourne PA, Lei JY, Yang X, Tickoo SK, Liu Z, Huang J and Di Sant Agnese PA. Expression of Novel Markers in Small Cell Carcinoma of the Prostate: Possible Therapeutic Targets. Mod Path. 2005. 18: S1; 173A. 95th Annual Meeting of the United States and Canadian Academy of Pathology, San Antonio, TX, February 2005. 14. Nigwekar P, Yao JL, di Sant'Agnese PA, Mayer RD, Reeder JE, Huang J. Overexpression of Heme Oxygenase-1 in Prostate Cancer. Presented at the 95th Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta, GA, February 2006. 15. Simon R, Bourne PA, di Sant’Agneses PA, Huang J and Yao JL. Mini Chromosome Maintenance Protein 6 Expression in the Prostate: a Tissue Microarray Analysis. Presented at the 95th Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta, GA, February 2006. 16. Golijanin DJ, Wood RW, Madeb RR, Silvers CR, Yao JL, Huang J, Messing EM, Reeder JE, Joseph JV. Intraoperative Visualization of Cavernous Nerves Using Near Infrared Fluorescence of Indocyanine Green in the Rat. Presented at the 101st Annual Meeting of the American Urological Association, Atlanta, GA, May 2006. 17. Simon R, di Sant'Agnese PA, Yao JL, Bourne PA, Bohrer KA and Huang J. Prostate Cancer is Associated with Increased Expression of Nuclear Cyclin D1. Accepted for presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007. 18. Li L, Simon R, Spauldin BO, Bourne PA, Yao JL, di Sant'Agnese PA, Xu H and Huang J. KOC is a Useful Marker for the Classification of Urothelial Neoplasms of the Bladder. Accepted for presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007. 19. Li L, Bourne PA, Yao JL, di Sant'Agnese PA, Zhuang Z, Yin C, Wu C and Huang J. Myosin VI, a Mediator of The P53-Dependent Cell Survival Pathway, is Overexpressed in Adenocarcinoma of the Prostate. Accepted for presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007. 20. Lester TR, Kohli M, Quinn A, Reeder JE, Yao JL, di Sant'Agnese PA, Bourne PA and Huang J. Expression of Thrombin in the Prostate: Implications for Carcinogenesis and Tumor-associated Hypercoagulation. Accepted for presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007. 21. Nigwekar P, Lester TR, Yang Q, Bourne PA, Yao JL, di Sant'Agnese PA, Zhai J, Wang H and Huang J. Overexpression of Human Carcinoma-Associated Antigen (HCA) in Pancreatic Adenocarcinoma. Accepted for presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007. 22. Nigwekar P, Wu C, Yao JL, Bourne PA, Li J, Zhuang Z, di Sant'Agnese PA, Walters DC and Huang J. Nucleophosmin, a Critical Regulator of Cell Proliferation, is Overexpressed in Prostate Cancer. Accepted for presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007. 23. Simon RA, Xu H, Bourne PA, Yao JL, Wei J, Liang S, Liu, J, di Sant'Agnese PA, Cheng L, and Huang J. CD44 is a Useful Marker for Prostatic Small Cell Carcinoma. 97th Annual Meeting, United States and Canada Academy of Pathology, Denver, CO 2008 24. Wagner DG, Scott G,Yang Q and Huang J. Stem Cell-Associated Markers Are Useful in Distinguishing Melanoma From Nevi. 98th Annual Meeting, United States and Canada Academy of Pathology, Boston, MA 2009 25. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang L-S, Yang Q and Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate Cancer Foundation Scientific Retreat. Reno, NV, Sept 2009 26. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang L-S, Yang Q and Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. NCI Translational Science Meeting, Tyson Corer, VA. Nov 2009 27. Mulholland DJ, Kobayashi N, Johnston M, Sun Z, Morim A, Wu L, Huang J, Wu H. Cooperativity between Pten loss and K-ras activation in promoting EMT and metastasis in murine prostate cancer. AACR Special Conference (EMT and Cancer Progression and Treatment) Arlington, Virginia, 2010 28. Clebanoff JL, Magyar C, Yao JL, di Sant'Agnese PA, Cheng L, Yang Q, Li X and Huang J. p53 Pathway is Involved in the Pathogenesis of Small Cell Carcinoma of the Prostate. 99th Annual Meeting, United States and Canada Academy of Pathology, Washington DC, 2010 29. Wagner D, Miller E, Yang Q, Scott G, Rubin BP and Huang J. Stem Cell-Associated Markers Distinguish Melanoma from Malignant Peripheral Nerve Sheath Tumor. 99th Annual Meeting, United States and Canada Academy of Pathology, Washington DC, 2010 30. Huss J, Raman S and Huang J. Kidney Biopsy for Tumors: Pathologic Interpretation and Clinical Significance. 100th Annual Meeting, United States and Canada Academy of Pathology, San Antonio, TX 2011 31. Miller E, Rettig M, Magyar C and Huang J. Strong and Diffuse Nuclear Staining for Phospho-c-Jun Distinguishes Clear Cell Renal Cell Carcinoma from its Mimickers. 100th Annual Meeting, United States and Canada Academy of Pathology, San Antonio, TX 2011 32. Palla B, Zhang H and Huang J. A Novel Method to Procure Fresh Prostate Tissue for Viable

Epithelial Cells. 100th Annual Meeting, United States and Canada Academy of Pathology, San Antonio, TX 2011